#$%^&*AU2014210598B220160225.pdf#####ABSTRACT A site-specific, pharmaceutical composition comprising: 5 (a) a therapeutic amount of at least one hemostatic agent, wherein the therapeutic amount is effective to reduce hematoma expansion or recurrent bleeding from a hemorrhagic condition in brain, when compared to a nontreated control； and (b) a pharmaceutically acceptable carrier, wherein the carrier comprises a plurality of 10 microparticles； the composition being characterized by: (i) dispersal of the therapeutic amount of the hemostatic agent throughout 15 each microparticle, in a core of the microparticle surrounded by a coating, adsorbed into the particles, or a combination thereof； (ii) its deposition in or on a biodegradable implant at an implant site in a cavity or space within the human brain occupied by a hematoma or in a subdural space on the surface of the brain； 20 (iii) sustained release of the hemostatic agent from the microparticles at the implant site to maintain a high concentration of the hemostatic agent locally and lower concentrations in the rest of the body, thus decreasing risk of unwanted systemic side effects； (iv) flowability of the hemostatic agent in cerebrospinal fluid from the 25 implant site to a site of bleeding in or on the brain.
